AlloVir Inc. [ALVR] fell -51.70% so far this year. What now?

Related

AlloVir Inc. [NASDAQ: ALVR] gained 15.53% on the last trading session, reaching $6.25 price per share at the time. The company report on April 20, 2022 that FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Posoleucel’s third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies.

Global Phase 3 multi-virus prevention trial initiated in March 2022 and is enrolling patients.

AlloVir Inc. represents 63.36 million in outstanding shares, while the company has a total market value of $422.94 million with the latest information. ALVR stock price has been found in the range of $6.17 to $8.51.

If compared to the average trading volume of 276.44K shares, ALVR reached a trading volume of 87653408 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about AlloVir Inc. [ALVR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALVR shares is $37.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALVR stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for AlloVir Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 19, 2021. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on August 24, 2020, representing the official price target for AlloVir Inc. stock. Previously, the target price had yet another raise to $49, while Morgan Stanley analysts kept a Overweight rating on ALVR stock.

The Average True Range (ATR) for AlloVir Inc. is set at 0.74 The Price to Book ratio for the last quarter was 1.76, with the Price to Cash per share for the same quarter was set at 3.67.

Trading performance analysis for ALVR stock

AlloVir Inc. [ALVR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.39. With this latest performance, ALVR shares dropped by -17.65% in over the last four-week period, additionally sinking by -73.39% over the last 6 months – not to mention a drop of -72.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALVR stock in for the last two-week period is set at 43.72, with the RSI for the last a single of trading hit 47.59, and the three-weeks RSI is set at 41.99 for AlloVir Inc. [ALVR]. The present Moving Average for the last 50 days of trading for this stock 7.64, while it was recorded at 5.69 for the last single week of trading, and 15.69 for the last 200 days.

AlloVir Inc. [ALVR]: A deeper dive into fundamental analysis

Return on Equity for this stock declined to -59.47, with Return on Assets sitting at -52.31.

AlloVir Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.

An analysis of insider ownership at AlloVir Inc. [ALVR]

There are presently around $139 million, or 39.30% of ALVR stock, in the hands of institutional investors. The top three institutional holders of ALVR stocks are: FMR LLC with ownership of 7,381,063, which is approximately 0.7% of the company’s market cap and around 6.80% of the total institutional ownership; VANGUARD GROUP INC, holding 2,793,583 shares of the stock with an approximate value of $15.11 million in ALVR stocks shares; and ARTAL GROUP S.A., currently with $12.57 million in ALVR stock with ownership of nearly 0% of the company’s market capitalization.

Positions in AlloVir Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 40 institutional holders increased their position in AlloVir Inc. [NASDAQ:ALVR] by around 1,663,625 shares. Additionally, 41 investors decreased positions by around 1,575,384 shares, while 12 investors held positions by with 22,400,962 shares. The mentioned changes placed institutional holdings at 25,639,971 shares, according to the latest SEC report filing. ALVR stock had 16 new institutional investments in for a total of 748,026 shares, while 12 institutional investors sold positions of 513,489 shares during the same period.